SGLT2 inhibitors (Jardiance, Farxiga, Invokana) lower blood sugar by removing glucose through the kidneys into the urine. Beyond glucose control, they provide significant cardiovascular and kidney protection. They are now first-line agents for type 2 diabetes patients with heart failure or chronic kidney disease.
SGLT2 inhibitors are a class of oral diabetes medications that work through a unique kidney-based mechanism. They are now among the most important drugs in type 2 diabetes management — not just for glucose control, but for their proven benefits on heart and kidney health.
How They Work
The kidneys normally filter and then reabsorb almost all glucose from the urine back into the bloodstream via the SGLT2 protein. SGLT2 inhibitors block this reabsorption, allowing glucose to pass into the urine and out of the body. This lowers blood sugar without requiring insulin — making hypoglycemia rare when used alone.
🫀 Beyond Blood Sugar: SGLT2 inhibitors are the only oral diabetes medications with FDA-approved indications for both reducing cardiovascular death (Jardiance, Farxiga) and slowing chronic kidney disease progression (Farxiga, Jardiance). They are recommended as first-line add-ons in patients with heart failure or CKD, regardless of HbA1c.
The Main Medications
| Generic Name | Brand | Key Approvals |
|---|---|---|
| Empagliflozin | Jardiance | T2D, CV death reduction, HF, CKD |
| Dapagliflozin | Farxiga | T2D, HF (with & without T2D), CKD |
| Canagliflozin | Invokana | T2D, CV risk reduction, CKD with T2D |
| Ertugliflozin | Steglatro | T2D only (no CV/renal outcome data) |
Glucose-Lowering Effectiveness
- HbA1c reduction: approximately 0.5–1.0%
- Weight loss: 2–4 kg (4–9 lbs) sustained
- Blood pressure reduction: modest (2–4 mmHg systolic)
- No hypoglycemia when used alone (does not stimulate insulin)
Cardiovascular & Kidney Benefits
Major outcome trials have established SGLT2 inhibitors as cardioprotective and nephroprotective:
- EMPA-REG (Jardiance): 38% reduction in cardiovascular death in patients with established CVD
- DECLARE-TIMI (Farxiga): 27% reduction in hospitalization for heart failure
- CANVAS (Invokana): 14% reduction in major adverse cardiovascular events
- DAPA-CKD (Farxiga) & EMPA-KIDNEY (Jardiance): Significant slowing of kidney disease progression — benefit seen even in non-diabetic CKD patients
Side Effects
- Genital yeast infections (mycotic infections): Most common side effect — ~10% of women, ~4% of men. Good hygiene and staying dry reduces risk.
- Urinary tract infections: Modestly increased risk. Drink adequate fluids.
- Volume depletion / dizziness: Increased urination can cause dehydration, especially in elderly patients or those on diuretics. Stay hydrated.
- Euglycemic DKA (rare): Diabetic ketoacidosis with normal or only mildly elevated blood sugar. Risk is higher in Type 1 diabetes (SGLT2 inhibitors are not FDA-approved for T1D), fasting states, surgery, or very low carbohydrate diets.
- Lower limb amputation risk (canagliflozin): Observed in CANVAS trial — use with caution in patients with peripheral artery disease or active foot ulcers.
🚨 Stop Before Surgery: Hold SGLT2 inhibitors 3–4 days before any elective surgery, major dental procedure, or colonoscopy prep due to euglycemic DKA risk. Always inform your surgical or procedure team.
Who Should Not Take SGLT2 Inhibitors
- eGFR <20 (severely reduced kidney function — not enough kidney function for the drug to work effectively)
- Type 1 diabetes (off-label; significantly increased DKA risk)
- Recurrent genital or urinary tract infections
- Active lower extremity ulcers or peripheral artery disease (especially canagliflozin)
- Pregnancy
Key Takeaways
- SGLT2 inhibitors lower blood sugar by removing glucose through the urine — no insulin stimulation, no hypoglycemia alone
- Jardiance and Farxiga have proven cardiovascular and kidney protection — now recommended for patients with heart failure or CKD
- HbA1c reduction ~0.5–1.0%, weight loss ~2–4 kg
- Main side effects: genital yeast infections, UTIs, and volume depletion
- Must be held 3–4 days before surgery due to risk of euglycemic DKA
- Not appropriate for severe kidney disease (eGFR <20) or Type 1 diabetes
Our Team Can Help
All five of our providers diagnose and manage endocrine conditions. Book with any member of our team:
Book an Appointment → or call 832-968-7003